^
    3ms
    GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=130, Terminated, Genmab | Completed --> Terminated; The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review of the data, market landscape, and strategic priorities.
    Trial termination
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)
    4ms
    GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=130, Completed, Genmab | Active, not recruiting --> Completed
    Trial completion
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)
    7ms
    GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=130, Active, not recruiting, Genmab | N=252 --> 130
    Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)
    7ms
    GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=252, Active, not recruiting, Genmab | Trial completion date: Dec 2026 --> Jul 2025 | Trial primary completion date: Mar 2025 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)
    1year
    GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=252, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)
    over1year
    GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=252, Recruiting, Genmab | Trial primary completion date: Mar 2025 --> Oct 2024
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)
    over1year
    GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=252, Recruiting, Genmab | Trial primary completion date: Oct 2024 --> Mar 2025
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)
    almost2years
    GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=252, Recruiting, Genmab | Trial completion date: Feb 2029 --> Dec 2026
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)
    over2years
    Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity. (PubMed, EBioMedicine)
    Based on these preclinical studies, a clinical trial was initiated to assess the clinical safety of HexaBody-CD38 in patients with MM.
    Preclinical • Journal • IO biomarker
    |
    CD38 expression
    |
    Darzalex (daratumumab) • erzotabart (GEN3014)
    over2years
    PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB (EHA 2023)
    GEN3014 showed potent CDC activity in vitro, with higher maximal kill compared to daratumumab, also under suboptimal complement conditions. GEN3014 induced a stronger decline of complement levels in patients compared to historical data of daratumumab, supporting its potential to induce enhanced CDC in patients. These findings support the ongoing phase 1/2 trial in patients with RRMM (NCT04824794) evaluating the safety and efficacy of GEN3014, which includes a head-to-head comparison with daratumumab.
    Clinical • PK/PD data • IO biomarker
    |
    Darzalex (daratumumab) • erzotabart (GEN3014)
    over2years
    GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=252, Recruiting, Genmab | Trial completion date: Jan 2024 --> Feb 2029 | Trial primary completion date: Apr 2023 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)
    almost3years
    GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=272, Recruiting, Genmab | N=152 --> 272
    Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)